The stock of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) hit a new 52-week high and has $15.46 target or 97.00% above today’s $7.85 share price. The 5 months bullish chart indicates low risk for the $350.92 million company. The 1-year high was reported on Oct, 5 by Barchart.com. If the $15.46 price target is reached, the company will be worth $340.39 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 507,878 shares traded hands. Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has risen 380.82% since March 2, 2016 and is uptrending. It has outperformed by 372.56% the S&P500.
Analysts await Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to report earnings on November, 8. They expect $-0.08 earnings per share, down 33.33% or $0.02 from last year’s $-0.06 per share. After $-0.11 actual earnings per share reported by Corbus Pharmaceuticals Holdings Inc for the previous quarter, Wall Street now forecasts -27.27% EPS growth.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Ratings Coverage
Out of 2 analysts covering Corbus Pharma (NASDAQ:CRBP), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Corbus Pharma has been the topic of 2 analyst reports since September 8, 2015 according to StockzIntelligence Inc. As per Monday, March 7, the company rating was initiated by Aegis Capital. JMP Securities initiated Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) on Tuesday, September 8 with “Mkt Outperform” rating.
According to Zacks Investment Research, “Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics to treat life threatening (orphan) inflammatory-fibrotic diseases. The Company’s lead product is Resunab (TM), an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and scleroderma. Corbus Pharmaceuticals Holdings, Inc. is based in Norwood, Massachusetts.”
Another recent and important Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) news was published by Benzinga.com which published an article titled: “Corbus Pharmaceuticals Could Achieve 3 Clinical Inflection Points Over The …” on October 05, 2016.
CRBP Company Profile
Corbus Pharmaceuticals Holdings, Inc., incorporated on December 18, 2013, is a clinical-stage pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. The Company’s product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis (CF), systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration (the FDA) has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.